The molecular cargo of
tumor-cell-derived exosomes (TEX) mimics that of parental
tumor cells. Thus, TEX could potentially serve as noninvasive
biomarkers of
cancer progression. However, separation of TEX from non-TEX in patients' plasma requires
tumor antigen-specific detection
reagents. CD44v3 has been of interest as a potential
biomarker of
disease progression in
HNSCC, because its overexpression in
tumor cells associates with poor outcome. Here, CD44v3+ TEX immunocaptured from plasma of 44
HNSCC patients and 7 healthy donors (HDs) were evaluated as potential
biomarkers of disease activity and stage. Exosomes were isolated from plasma of by size exclusion chromatography. Using anti-CD44v3 or anti-CD3 mAbs on beads, CD44v3+ TEX CD3(-)TEX-enriched exosomes were immunocaptured from supernatants of nonmalignant or
HNSCC cell lines and from patients' plasma. On-bead flow cytometry was used for the detection of FAS-L, PD-L1, TGFF-β. CSPG4 or EGFR on exosomes. The TEX expression profiles were correlated to clinicopathological parameters. Relative florescence intensity (RFI) values for CD44v3 were higher (p < .01) on TEX from
HNSCC cell lines or on CD44v3+ CD3(-) plasma-derived exosomes. RFI values of CD44v3 on CD3(-) exosomes were higher (p < .005) in patients than in HDs and correlated (p < .05) with the UICC stage and
lymph node metastasis. In
HNSCC patients, CD44v3+ exosomes higher levels of immunosuppressive
proteins compared to CD44v3(-) exosomes (p < .05-p < .005), and RFI values for these markers correlated with higher disease stages and
lymph node metastasis. Isolation of CD44v3+ exosomes by immunocapture allowed for enrichment of TEX which are potentially promising liquid
biomarkers of the
tumor burden and disease stage in
HNSCC.